Biogen Stock Outlook: Is Wall Street Bullish or Bearish?

Biogen Inc. (BIIB), based in Cambridge, Massachusetts, is a leading biotechnology company focused on developing and delivering innovative therapies for neurological and neurodegenerative diseases. With a market cap of $20.6 billion, Biogen specializes in treatments for conditions such as multiple sclerosis (MS), Alzheimer’s disease, spinal muscular atrophy, and other neurological disorders. 

Shares of this leading biotechnology company have significantly underperformed the broader market over the past year. BIIB has declined 36.4% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 20.7%. In 2025, the stock remains under pressure, down 8% year-to-date, trailing the SPX’s 2.2% gain.